Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

August 10, 2018: By Joan McKenna

Spark Therapeutics’ retinal gene therapy, Luxturna (voretigene neparvovec-rzyl), accounted for $4.3 million in net sales in Q2-2018, the Philadelphia company announced Aug. 7.

Spark said it shipped 12 vials of Luxturna during the quarter, and patients were now being treated at six treatment centers.

Spark said it posted total revenues during the quarter of $25.2 million; Pfizer agreements accounted for the remaining $20.9 million.

Spark reported $656.8 million in cash, cash equivalents, and marketable securities as of June 30.

Spark is currently focused on its Phase III candidate for hemophilia B. The company also is developing a Phase I/II candidate for choroideremia.

Luxturna gained US approval in December 2017 for the treatment of patients with retinal dystrophy due to confirmed mutation of the biallelic RPE65 gene.

Spark launched Luxturna in Q1-2018, with three patients treated and Luxturna net sales totaling $2.4 million in the quarter.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Astellas Acquires Quethera, Glaucoma Gene Therapy Candidate in Potential $109 Million Deal

STAAR Surgical Completes $77.9 Million Public Offering

Rheon’s eyeWatch Adjustable Glaucoma Device Implanted in Three UK Patients

Carl Zeiss Meditec Revenues Total $356 Million in Third Quarter of FY2018, a 12.7 Percent Increase

Kedalion Therapeutics Raises $5 Million in Series A Financing

Second Sight Reports 17 Argus II Implantations in Q2-2018; Firm to Focus on Orion System

Iridex Revenues Grow 3 Percent in Q2-2018

Omeros Revenues Drop Steeply with Omidria’s Temporary Loss of Pass-through Status

Shire’s Xiidra Delivers $100 Million in Q2-2018 Revenues, an Increase of 75 Percent

STAAR Posts Q2-2018 Revenues of $33.9 Million, a 55 Percent Increase

Avedro Names Glaukos CEO Thomas Burns to its Board

Aerie Licenses DSM’s Bioerodible Implant Technology for Ophthalmic Use for $15 Million

Alimera’s Q2-2018 Revenues Increase 5 Percent

Presbyopia Therapies’ PRX Meets Phase IIb Endpoints

Clinical Study of Imprimis’ Dropless Formulation Set to Begin in Canada

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT